Mandate

Vinge advises J.P. Morgan, Nordea and SEB Enskilda in connection with SAS rights issue

February 09, 2010

Vinge is advising J.P Morgan, Nordea and SEB Enskilda in connection with SAS AB’s new issue of ordinary shares for approximately SEK 5 billion with pre-emption rights for the company’s existing shareholders. J.P. Morgan, Nordea and SEB Enskilda which are acting as Joint Global Co-ordinators, Joint Lead Managers and Joint Bookrunners in the rights issue have, together with DnB NOR Markets, the Royal Bank of Scotland and Danske Markets, confirmed their willingness, subject to certain conditions, to severally enter into underwriting agreements in respect of 42.4 per cent of the shares in the issue.

SAS AB is listed on NASDAQ OMX Stockholm, NASDAQ OMX Copenhagen and Oslo Børs.

Vinge’s team primarily consisted of partners Göran Nyström, Rikard Stenberg and Lennart Larsson together with associates Johan Thiman, Johan Norström and Mårten Svensson.

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026